# Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

> **NCT04121442** · PHASE1,PHASE2 · COMPLETED · sponsor: **Buzzard Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** Isunakinra
- **BIOLOGICAL:** PD-(L)1 Inhibitor

## Key facts

- **NCT ID:** NCT04121442
- **Lead sponsor:** Buzzard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-07-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121442, "Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04121442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*